ESCC
Clinical trials for ESCC explained in plain language.
Never miss a new study
Get alerted when new ESCC trials appear
Sign up with your email to follow new studies for ESCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple therapy hope for tough esophageal cancer
Disease control Not yet recruitingThis study tests a new three-drug combination for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The drugs include an antibody-drug conjugate (becotatug vedotin) that targets cancer cells, an immunotherapy (tislelizumab), and stan…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 01, 2026 17:26 UTC
-
New triple-drug combo aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis early-phase trial tests whether giving three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. The study will enroll 22 adults aged 18-75 with stage IIA-IIIB disease who have …
Matched conditions: ESCC
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 01, 2026 16:06 UTC
-
New combo targets tough esophageal cancer in 33-patient trial
Disease control Not yet recruitingThis study tests a combination of two drugs (SHR-1701 and irinotecan liposome) in 33 people with esophageal squamous cell carcinoma who have already received immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. Participants must have meas…
Matched conditions: ESCC
Phase: PHASE2 • Sponsor: Zhigang Li • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New combo therapy aims to extend life in elderly esophageal cancer patients
Disease control Not yet recruitingThis study tests a combination of the chemotherapy drug TAS-102 and radiation therapy in people aged 65-85 with advanced esophageal cancer that has not spread widely. The goal is to find the best dose and see if the treatment helps patients live longer and controls the cancer. Ab…
Matched conditions: ESCC
Phase: PHASE1, PHASE2 • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC